Search
Innovation that advances cancer care
Seagen is developing a new generation of targeted, empowered treatments to advance cancer care. We’ve designed our pipeline with patients in mind, focusing on therapies that have the potential to address significant unmet medical needs.
The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory ities.
Program
Phase
Phase
R/R Diffuse Large B-Cell Lymphoma
SGN35-31: + lenalidomide, rituximab
1L Hodgkin lymphoma (HL)
SGN35-27: + nivolumab, doxorubicin and dacarbazine
1L HL or PTCL (unfit for combination chemotherapy)
SGN35-15: Monotherapy
R/R HL and PTCL
SGN35-28: Retreatment
R/R HL (pediatrics)
CheckMate 744: + nivolumab
1L Locally advanced or metastatic urothelial cancer
EV-302: + pembrolizumab, +/- chemotherapy
Locally advanced or metastatic urothelial cancer*
EV-301: Post PD(L)-1 and post platinum chemotherapy
Locally advanced or metastatic urothelial cancer*†
EV-201: Cohort 2 post anti-PD(L)-1 or post PD(L)-1 inhibitor, platinum naïve and cisplatin ineligible
1L/2L Locally advanced or metastatic urothelial or muscle-invasive cancer
EV-103: +/- pembrolizumab or other anti-cancer agents
1L Muscle invasive bladder cancer
EV-303/KEYNOTE-905: + pembrolizumab
1L Muscle invasive bladder cancer
EV-103: +/- pembrolizumab
Locally advanced or metastatic solid tumors
EV-202: Monotherapy
HER2CLIMB-02 – Metastatic HER2+ breast cancer
HER2CLIMB-02: + T-DM1
R/R HER2+ metastatic colorectal cancer†
MOUNTAINEER: + trastuzumab
1L HER2+ gastric cancer
+ trastuzumab, oxaliplatin
Recurrent or metastatic cervical cancer†‡
innovaTV 204: Monotherapy
1L/2L Recurrent or metastatic cervical cancer
innovaTV 205: + other anti-cancer agents and monotherapy
R/R Metastatic solid tumors
innovaTV 207: Monotherapy
Platinum-resistant ovarian cancer
innovaTV 208: Monotherapy
1L Metastatic triple-negative breast cancer
+ pembrolizumab
R/R Metastatic breast cancer (HR+/HER2-)
+ trastuzumab
R/R Metastatic solid tumors
Monotherapy
R/R Multiple myeloma
+/- dexamethasone
R/R Pancreatic cancer
+/- pembrolizumab, gemcitabine, nap-paclitaxel
R/R Solid tumors
Monotherapy
R/R MDS/AML
Monotherapy
R/R Solid tumors and lymphoma
+/- pembrolizumab
R/R Solid tumors
Monotherapy
Lymphoma
1L=frontline/first-line, 2L=second-line, R/R=relapsed/refractory, PTCL=peripheral T-cell lymphoma.
*Enrollment Complete
†Pivotal Trial
‡Top-line Data Reported
Request additional information about an investigational therapy or report an adverse event.